company background image
PYC

PYC Therapeutics ASX:PYC Stock Report

Last Price

AU$0.072

Market Cap

AU$229.0m

7D

5.9%

1Y

-40.0%

Updated

08 Feb, 2023

Data

Company Financials +

PYC Stock Overview

PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of drug solutions in the areas of ribonucleic acid therapeutics in Australia.

PYC fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

PYC Therapeutics Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for PYC Therapeutics
Historical stock prices
Current Share PriceAU$0.072
52 Week HighAU$0.13
52 Week LowAU$0.057
Beta0.42
1 Month Change9.09%
3 Month Change-10.00%
1 Year Change-40.00%
3 Year Change16.13%
5 Year Change148.28%
Change since IPO-72.31%

Recent News & Updates

Here's Why We're Watching PYC Therapeutics' (ASX:PYC) Cash Burn Situation

Jan 25
Here's Why We're Watching PYC Therapeutics' (ASX:PYC) Cash Burn Situation

Recent updates

Here's Why We're Watching PYC Therapeutics' (ASX:PYC) Cash Burn Situation

Jan 25
Here's Why We're Watching PYC Therapeutics' (ASX:PYC) Cash Burn Situation

Companies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In Growth

Jul 31
Companies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In Growth

We're Not Very Worried About PYC Therapeutics' (ASX:PYC) Cash Burn Rate

Mar 28
We're Not Very Worried About PYC Therapeutics' (ASX:PYC) Cash Burn Rate

Non-Executive Chair of the Board Alan Tribe Just Bought A Handful Of Shares In PYC Therapeutics Limited (ASX:PYC)

Feb 20
Non-Executive Chair of the Board Alan Tribe Just Bought A Handful Of Shares In PYC Therapeutics Limited (ASX:PYC)

Have Insiders Been Selling PYC Therapeutics Limited (ASX:PYC) Shares?

Jan 26
Have Insiders Been Selling PYC Therapeutics Limited (ASX:PYC) Shares?

What You Need To Know About PYC Therapeutics Limited's (ASX:PYC) Investor Composition

Dec 22
What You Need To Know About PYC Therapeutics Limited's (ASX:PYC) Investor Composition

We Think PYC Therapeutics (ASX:PYC) Can Easily Afford To Drive Business Growth

Nov 17
We Think PYC Therapeutics (ASX:PYC) Can Easily Afford To Drive Business Growth

Shareholder Returns

PYCAU BiotechsAU Market
7D5.9%3.1%0.4%
1Y-40.0%16.4%0.4%

Return vs Industry: PYC underperformed the Australian Biotechs industry which returned 16.4% over the past year.

Return vs Market: PYC underperformed the Australian Market which returned 0.4% over the past year.

Price Volatility

Is PYC's price volatile compared to industry and market?
PYC volatility
PYC Average Weekly Movement9.6%
Biotechs Industry Average Movement8.9%
Market Average Movement8.4%
10% most volatile stocks in AU Market15.5%
10% least volatile stocks in AU Market3.4%

Stable Share Price: PYC is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: PYC's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2001n/aRohan Hockingshttps://pyctx.com

PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of drug solutions in the areas of ribonucleic acid therapeutics in Australia. The company’s preclinical development programs include VP-001, drug program for retinitis pigmentosa type 11; and PYC-001, a drug program for the treatment of autosomal dominant optic atrophy. It also focuses on the development of programs for kidney, retinal, and central nervous system diseases.

PYC Therapeutics Limited Fundamentals Summary

How do PYC Therapeutics's earnings and revenue compare to its market cap?
PYC fundamental statistics
Market CapAU$229.03m
Earnings (TTM)-AU$13.86m
Revenue (TTM)AU$16.04m

14.3x

P/S Ratio

-16.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PYC income statement (TTM)
RevenueAU$16.04m
Cost of RevenueAU$0
Gross ProfitAU$16.04m
Other ExpensesAU$29.91m
Earnings-AU$13.86m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.0044
Gross Margin100.00%
Net Profit Margin-86.41%
Debt/Equity Ratio0%

How did PYC perform over the long term?

See historical performance and comparison